CTOs on the Move

Oncorus

www.oncorus.com

 
Oncorus, Inc. is a lean early-stage biotechnology company developing a next-generation immunotherapy platform to treat cancer. Oncorus was founded by well-known biotechnology entrepreneurs and is backed by MPM Capital. Oncorus is a leader in corporate philanthropy, and has taken a pledge to donate a portion of product sales to fund promising cancer research and to support cancer care in the developing world. We are located in Kendall Square, Cambridge, MA.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.oncorus.com
  • 450 Kendall St 4th Floor
    Cambridge, MA USA 02142
  • Phone: 857.320.6402

Executives

Name Title Contact Details

Funding

Oncorus raised $57M on 07/20/2016
Oncorus raised $61M on 12/16/2016
Oncorus raised $79.5M on 08/21/2019
Oncorus raised $57M on 02/12/2021
Oncorus raised $20M on 04/05/2022

Similar Companies

ProtonDx

Because your organisation needs certainty when testing for Covid-19

Bayhill Therapeutics

Bayhill Therapeutics is a Palo Alto, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Beacon Food Safety

Beacon Food Safety is a Greenwood Vlg, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vedanta Biosciences

The trillions of microbes that call us home – the human microbiome – perform critical functions that preserve our health including helping develop our immune system, manufacturing nutrients such as vitamins, and harvesting energy from the diet. Alterations of the human microbiome are increasingly recognized as a key factor in autoimmune, metabolic, infectious and many other diseases. For millions of years, humans have co-evolved with this community of microbes, communicating in an ancient language that holds critical clues about how autoimmune and infectious diseases develop. This language is based on a system of signals that our resident microbes use to successfully colonize us, such as byproducts of bacterial metabolism and factors that bacteria use to adapt to human niches. Recent discoveries have shown that most of these signals do not lead to disease, rather, they promote our long-term survival. Vedanta Biosciences is developing an innovative class of therapies that modulate pathways of interaction between the human microbiome and the host immune system. Vedanta Biosciences was co-founded by PureTech and a group of world renowned experts in immunology and microbiology.